BA11: Randomised Phase III Study Comparing Paclitaxel/Cisplatin/Gemcitabine and Cisplatin/Gemcitabine in Patients with Metastatic or Locally Advanced Urothelial Cancer without Prior Systemic Therapy*

By  

UroOncology, Vol. 2, Iss. 2, 2002-01 ,pp. : 55-56

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group

By Schilder Russell   Blessing John   Pearl Michael   Rose Peter  

Investigational New Drugs, Vol. 22, Iss. 3, 2004-08 ,pp. : 343-349

Springer Publishing Company

Access to resources Recommend Favorite

Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: A Southwest Oncology Group study

By Whitehead Robert   McCoy Sheryl   Macdonald John   Rivkin Saul   Neubauer Marcus   Dakhil Shaker   Lenz Heinz-Josef   Tanaka Michael   Abbruzzese James  

Investigational New Drugs, Vol. 24, Iss. 4, 2006-07 ,pp. : 335-341

Springer Publishing Company

Access to resources Recommend Favorite

A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study

By Armstrong Deborah K.   Blessing John A.   Rader Janet   Sorosky Joel I.  

Investigational New Drugs, Vol. 21, Iss. 4, 2003-11 ,pp. : 453-457

Springer Publishing Company

Access to resources Recommend Favorite

Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer

By Vansteenkiste Johan   Canon Jean-Luc   Riska Henrik   Pirker Robert   Peterson Patrick   John William   Mali Pekka   Lahn Michael  

Investigational New Drugs, Vol. 23, Iss. 3, 2005-06 ,pp. : 263-269

Springer Publishing Company

Access to resources Recommend Favorite